Stevenage Stevenage is the 3rd largest Cell and Gene Therapy (CGT) location Globally, behind Boston and San Francisco, yet it accounts for 68% of capital raised. CGT is projected to grow 30% annually to become a $14bn p.a. global market by 2025. Importantly, CGT is not an isolated strand of life sciences but highly connected, evidenced by the make-up of the Stevenage Bioscience Catalyst (SBC), with 70% of companies not directly CGT. Stevenage is already a critical location in developing the UK’s aspiration to become a global leader in life sciences and its value will be further enhanced by the GSK/Reef Group/UBS joint venture to deliver over 1,000,000 sq ft over 33 acres at GSK’s existing campus. Lateral have acquired a site to deliver c.150,000 sq ft in advance of GSK’s phase 1 to satisfy the considerable depth of demand, both domestic and international. Ongoing
Shad Thames, SE122 Shad Thames is a RIBA award winning building designed by Hopkins architects and was formerly the home of the Conran Group. Lateral have commissioned the prestigious Squire & Partners to retain and enhance the property to create 16,000 sq ft of well-crafted, high quality and sustainable office space that will continue to stand the test of time. The result is a highly engaging, sustainable scheme with riverside views, an abundance of natural light, ventilation, and outdoor space. Lateral will launch Ampers& in 22 Shad Thames and are further commissioned to brand, market, and interior design the scheme. Lateral are in talks to pre-let the entirety of the building. Ongoing
9
Made with FlippingBook - professional solution for displaying marketing and sales documents online